Microbix granted patent on its Vaccine Technology
Microbix Biosystems Inc. announced that it has been granted a patent by the Canadian Patent Office for its Vaccine Technology. This technology holds the promise of significantly boosting global production of influenza vaccines.
"This is a major milestone for Microbix as we move towards commercializing this important technology," said William J. Gastle, Chairman and CEO of the Company. "This is the first of a series of patents we expect will be granted in international markets where influenza vaccines are manufactured."
Last year, an independent laboratory confirmed that the Microbix' vaccine technology delivers a two-fold increase in the yield of human influenza virus from eggs. The independent evaluation was conducted by Dr. Todd Hatchette, the Director of Virology and Immunology at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. Dr. Hatchette is a specialist in the field of influenza virus.
Other news from the department research and development
